![]() |
|
|
Vol. 295, Issue 3, 1031-1042, December 2000
-Opioid Agonists
on Locomotor Activity in Mice
Departments of Neuroscience (A.K., S.-O.Ö.) and Clinical
Neuroscience (J.S., L.T.), Karolinska Institutet, Stockholm, Sweden
The
-opioid agonists U50488H, bremazocine, and BRL52537, and
the µ-opioid agonist morphine were compared in their ability to
modify spontaneous motor activity in male NMRI mice. Higher, analgesic
doses of the
-agonists reduced rearing, motility, and locomotion in
nonhabituated mice. These effects, as well as the analgesic action of
U50488H, were blocked by the selective
-opioid antagonists
nor-binaltorphimine and DIPPA. In contrast, lower, subanalgesic doses
(1.25 and 2.5 mg/kg for U50488H; 0.15 and 0.075 mg/kg for bremazocine,
and 0.1 mg/kg for BRL52537) time dependently increased motor activity.
The stimulatory effects of U50488H and bremazocine were not observed in
habituated animals and were reduced by dopamine depletion.
Surprisingly, the stimulatory effects of U50488H and bremazocine were
not blocked by nor-binaltorphimine and DIPPA but they were completely
eliminated by naloxone (0.1 mg/kg). The effects of morphine were
dose-dependent; an initial limited suppression was followed by
increased motility and locomotion (but not rearing) with a peak effect
at 20 mg/kg both in habituated and nonhabituated mice. The selective
µ-opioid antagonist
-funaltrexamine blocked morphine-induced motor
stimulation and analgesia but failed to affect the analgesic and motor
stimulatory effects of U50488H. The results indicate that
-opioid
agonists interact with different functional subtypes of opioid
receptors. A stimulatory, naloxone-sensitive but
nor-binaltorphimine- and DIPPA-insensitive subtype of opioid receptor appears to operate only when the dopamine system is tonically active in nonhabituated animals. At higher doses,
-agonists produce analgesia and motor suppression, effects mediated by a "classic" (inhibitory)
-opioid receptor.
This article has been cited by other articles:
![]() |
J. Fichna, A. Janecka, J. Costentin, and J.-C. Do Rego The Endomorphin System and Its Evolving Neurophysiological Role Pharmacol. Rev., March 1, 2007; 59(1): 88 - 123. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. V. Khroyan, N. T. Zaveri, W. E. Polgar, J. Orduna, C. Olsen, F. Jiang, and L. Toll SR 16435 [1-(1-(Bicyclo[3.3.1]nonan-9-yl)piperidin-4-yl)indolin-2-one], a Novel Mixed Nociceptin/Orphanin FQ/{micro}-Opioid Receptor Partial Agonist: Analgesic and Rewarding Properties in Mice J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 934 - 943. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Wang, X. Sun, L. M. Bohn, and W. Sadee Opioid Receptor Homo- and Heterodimerization in Living Cells by Quantitative Bioluminescence Resonance Energy Transfer Mol. Pharmacol., June 1, 2005; 67(6): 2173 - 2184. [Abstract] [Full Text] [PDF] |
||||